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Abstract
Evidence from epidemiological and experimental studies has shown that non-steroidal anti-inflammatory drugs
(NSAIDs) reduce the risk of colorectal cancer (CRC). The function of NSAIDs and the molecular targets for
chemopreventive effects on CRC have been extensively studied and their data were reported. However, the relation
between NSAIDs and the risk factors of CRC have not been fully elucidated yet. Thus, relations between NSAIDs and
the risk factors of CRC, such as overweight and obesity, alcohol, aging, hypertriglyceridemia and smoking, are
summarized with our data and with recent reported data in this review.
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Background
Non-steroidal anti-inflammatory drugs (NSAIDs) relieve
pain, reduce inflammation, lower fevers and prevent
blood from clotting. Thus, NSAIDs are used to treat in-
flammatory conditions such as arthritis. One of the trad-
itional NSAIDs, aspirin, was used to protect against
heart disease. Conversely, NSAIDs can increase the risk
of gastrointestinal (GI) bleedings/ulcer and interfere with
kidney function. The severity of side effects increases by
taking NSAIDs longer.
A large number of epidemiological and experimental
studies have shown that NSAIDs reduce the risk of colo-
rectal cancer (CRC). Meta-analysis of randomized trials
revealed that use of aspirin for approximately 5 years re-
duces incidence and mortality due to CRC by 30–40 %
after 20 years of follow-up [1].
The effectiveness of NSAIDS may be attributed to
their potent inhibition of cyclooxygenase (COX) en-
zymes because COX-2 expression and prostaglandin
(PG) E2 synthesis are elevated in CRC. The COXs/PGH
synthases have two enzymes, COX-1 and COX-2, and
COX is the limiting enzyme of the PG synthesis
pathway. The constitutive enzyme COX-1 has low ex-
pression in normal human colorectal tissue, whereas the
inducible enzyme COX-2 is elevated in tissue involved
in inflammation and in cancer. Traditional NSAIDs
block the actions of both COX-1 and COX-2, and select-
ive COX-2 inhibitors are a special category of NSAIDs.
In addition, aspirin can inhibit proliferation and induce
apoptosis of colon cancer cells [2]. The inhibition and
induction by aspirin include the following: (i) the inter-
ruption of nuclear factor kappa B (NF-κB), (ii) the inter-
ruption of extracellular signal-regulated kinases, (iii) the
induction of caspase 8 and 9, and (iv) the inhibition of
β-catenin signaling.
As shown above, the function and molecular targets of
NSAIDs have been well studied, and several pieces of
evidence have shown their chemopreventive effects on
CRC. However, the relation between NSAIDs and the
risk factors of CRC have not been well examined. In this
review, such relationships are summarized with our data
and recent reported data in the text, Table 1 and 2.
Risk factors of colorectal cancer
A risk factor is any attribute, characteristic or exposure
of an individual that increases the likelihood of develop-
ing a disease or injury [3]. In the case of cancer, it is de-
fined as factors that increase the chance of developing
cancer. Some people with several risk factors never de-
velop cancer. There is an intensity of correlation
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between risk factors and cancer. Thus, there might be
some weak risk factors of which we are not aware.
Several risk factors of CRC have been demonstrated to
date. The World Health Organization (WHO) lists fac-
tors that are convincing evidence for the risk of CRC in
daily life as follows: (i) consuming red meat, (ii) consum-
ing processed meat, (iii) alcoholic drinks (men), (iv) body
fatness / abdominal fatness, and (v) adult attained height
increase [4]. Other risk factors are reported as aging [5]
and a family history of CRC. Several medical histories of
diseases are known to increase the risk of CRC, such as
(i) genetic predisposition including familial adenomatous
polyposis and hereditary nonpolyposis CRC, (ii) high-
risk adenoma, (iii) inflammatory bowel disease, (iv) type-
2 diabetes, and (v) hypertriglyceridemia [6]. Moreover,
smoking is a strong factor in the development of colo-
rectal adenoma [7].
From recent published literature, we took particular
note of overweight and obesity, alcohol, aging, hypertri-
glyceridemia and smoking. The relation between each
risk factor and NSAIDs is described below.
Obesity and NSAIDs
Obesity is an important risk factor for CRC [8], and
there is a significant positive correlation between body
mass index (BMI) and CRC risk [9, 10]. Visceral abdom-
inal fat area measured by CT scan is more significantly
associated with colorectal adenoma [11]. Visceral fat ac-
cumulation causes increases in adipokines such as leptin,
inflammatory cytokines such as tumor necrosis factor
(TNF) α and interleukin (IL)-6, and growth factors such
as insulin-like growth factor (IGF)-I and vascular endo-
thelial growth factor (VEGF) [12, 13]. These factors
cause chronic low-grade inflammatory states, increased
proliferation and angiogenesis, and promote colon car-
cinogenesis [12, 13].
The use of NSAIDs is associated with reduced risk of
inflammation-associated cancers, and obesity-related
cancers are included in inflammation-related cancers
[14]. Compared with non-users of NSAIDs, lower risk of
obesity-related cancers in NSAID users (hazard ratio
(HR) = 0.88; 95 % confidence interval (CI), 0.85–0.92)
has been reported [14]. Although the preventive effects
of aspirin and NSAIDs on obesity-related cancers are in-
conclusive, there are several reports showing that aspirin
reduced risks of obesity-related cancers including CRC,
particularly among obese people. In the Aspirin/Folate
Polyp Prevention Study, a randomized controlled trial of
aspirin and folic acid to prevent colorectal adenoma, a
daily dose of 325 mg aspirin reduced the risk ratio for
advanced adenomas compared with placebo among
obese subjects (relative risk (RR) = 0.44; 95 % CI, 0.17–
1.10) but not among those with normal weight (RR =
1.23; 95 % CI, 0.55–2.77) [15]. In the CAPP2 study that
recruited participants with Lynch syndrome, CRC risk
was 2.41x greater for obese participants (95 % CI,
1.06–2.96; P = 0.03) than for underweight and normal-
weight participants, and the obesity-related excess risk
of CRC was confined to those randomly assigned to
the aspirin placebo group (adjusted HR = 2.75; 95 %
CI, 1.12–6.79, P = 0.03), but the risk was abrogated in
those taking aspirin [16].
PGE2 levels in rectal mucosa have been reported to be
positively associated with BMI [17]. PGE2 has been shown
to promote colorectal carcinogenesis [18] and metastasis
[19] in mouse models, and inhibition of PGE2 synthesis is
a potential target for prevention of CRC [20]. Therefore,
decrease of obesity-related CRC by NSAID use could be
due to inhibition of PGE2 production.
Obesity causes insulin resistance with hyperglycemia
and hyperinsulinemia, and these contribute to tumor de-
velopment [21]. Metformin, an insulin resistance-
improving, anti-diabetic agent, has been reported to re-
duce risks of various cancers including colon cancer in
diabetic and non-diabetic populations [22, 23]. Metformin
inhibits cell proliferation via activation of AMP-activated
protein kinase (AMPK) [24]. Serum adiponectin is de-
creased in obese people, and also activates AMPK and in-
hibits cell proliferation of colon cancer cells [24]. Recently,
it has been reported that aspirin activates AMPK and in-
hibits mTOR signaling in colon cancer cells [25]. Not all,
but several NSAIDs, such as salicylic acid, ibuprofen or
diclofenac, which have acidic structures, also induce
AMPK activation [26, 27]. This effect is considered to be a
COX-independent anti-inflammatory property of aspirin
and a subgroup of NSAIDs and may contribute to de-
crease obesity-related cancer risks.
Table 1 Effects of NSAIDs on risk factors of CRC
Risk factors of CRC NSAIDs effects on each factors
Obesity Lose weight and reduce the BMI




BMI body mass index, CRC colorectal cancer, GI gastrointestinal
NSAIDs Non-steroidal anti-inflammatory drugs
Table 2 Effects of NSAIDs plus each risk factors on CRC risk
Risk factors of CRC NSAIDs effects on CRC risk
Obesity Decreasing [14–16]
Alcohol Protection in a social drinker
Aging ー
Hypertriglyceridemia Decreasing [49, 50]
Smoking Increasing [57–59]
CRC colorectal cancer, NSAIDs Non-steroidal anti-inflammatory drugs
Hamoya et al. Genes and Environment  (2016) 38:6 Page 2 of 7
Alcohol and NSAIDs
In a meta-analysis of cohort and case–control studies,
there are reports describing moderately increased risks
of CRC with a dose–response relation for rising alcohol
consumption. A polled analysis of eight cohort studies
also recorded a dose–response relation between the risk
of CRC and the amount of alcohol consumption [28].
The mechanisms by which alcohol intake exerts its
carcinogenic effect are not fully understood yet. Acetal-
dehyde, a metabolite of alcohol, is implicated in esopha-
geal carcinogenesis but is not strongly implicated in
colorectal carcinogenesis. Recently, single nucleotide
polymorphisms (SNPs) in the alcohol dehydrogenase,
ADH1B, and aldehyde dehydrogenase, ALDH2, of mod-
erate/heavy drinkers were shown to be contributing fac-
tors for CRC [29]. Aspirin and salicylate could inhibit
both human ADH (metabolize ethanol to acetaldehyde)
and ALDH (degradation of acetaldehyde) activities [30].
To date, the effect of aspirin on acetaldehyde production
is not fully understood yet.
Ethanol is known as an irritant for the digestive tract.
Ethanol intake is known to be an independent risk factor
for GI bleeding. It is posited that the GI bleeding risk
from aspirin is high in individuals who consume three
or more alcoholic drinks every day [31].
Several reports suggest that ethanol exposure alters the
cytokine levels and inflammatory status in a variety of tis-
sues in vitro and in vivo, including the colon [32, 33]. Fur-
thermore, chronic alcohol intake promoted intestinal
tumorigenesis and tumor invasion in ApcMin/+ mice [34].
In a report, Wimberly et al. suggested that mast cell-
mediated inflammation could be one of the mechanisms
by which alcohol promotes intestinal carcinogenesis.
Recently, Landi and colleagues [35] studied the associ-
ation between SNPs in the IL-6, IL-8, TNFα and PPARG
genes and the risk of CRC by a hospital-based case con-
trol study. These genes are known to play important
roles in inflammation of the colorectum, and common
allelic variants are related to changes in biological func-
tions in the inflammation pathway. In their study, Landi
and colleagues observed an association between in-
creased CRC risk and the C-allele of a SNP −174 G > C
in the IL-6 gene (Odds ratio (OR) = 1.65, 95 % CI, 0.99–
2.74). Several reports showed the association of C-allele
carriers with inflammatory-related conditions, such as
increased plasma levels of C-reactive protein [36], higher
serum levels of IL-6 after coronary artery bypass sur-
gery [37] and asymptomatic carotid artery atheroscler-
osis [38]. In terms of CRC risk, the effect of alcohol
drinking was evident only in the subgroup of IL-6 C-
allele carriers (OR = 2.19, 95 % CI, 1.3–3.7), and the
use of NSAIDs halved the risk from 2.02 (95 % CI,
1.38–2.95) to 1.02 (95 % CI, 0.65–1.61) in the carriers of
the C-allele.
These reports suggest that the carcinogenic effect of
alcohol may be partly through the induction of acetal-
dehyde and inflammation, and NSAID use may effect-
ively protect CRC development in a social drinker.
Aging and NSAIDs
Disruption of normal tissue function dramatically accel-
erates in old age. Aging is the greatest risk factor for
numerous pathologies, including cancer, stroke, neuro-
degenerative disorders, heart disease and type-2 diabetes
[5]. Chronic inflammation is one of the main processes
that contributes to age-related disease and causes dis-
ruption of normal functioning of tissues. Notably, there
is a robust increase of mRNA and secretion of numerous
cytokines, chemokines, growth factors and proteases in
the senescent cells, and these cells may cause a low level
of chronic inflammation systemically during aging [39].
Yeast, nematodes and flies have been recognized as ex-
cellent model systems for studying the underlying mech-
anism of aging and identifying chemicals altering
longevity, mainly because of their short lifespans. A grow-
ing number of reports showed the effects of NSAIDs on
the lifespan extension in yeast [40], nematodes [40, 41],
flies [40, 42] and mice [43]. He et al. [40] reported that
ibuprofen extended the replicative life span of Saccharo-
myces cerevisiae cells by destabilizing the high-affinity
tryptophan transporter. He et al. also found that ibuprofen
caused small size at birth and moderate delay in initiation
of cell division, which was observed in most long-lived
yeast mutants. Meanwhile, celecoxib extended both mean
and maximum lifespans in C. elegans [41]. The physical
health, as indicated by the age-associated decay rate of
motor activity, was also significantly improved in
celecoxib-treated nematodes without affecting the nutri-
tional value. However, no homologs of mammalian COXs
have been identified in unicellular organisms, including C.
elegans. Furthermore, as analogs of celecoxib that lacked
COX-2 inhibitory activity also exhibited a similar effect on
nematode lifespan, the anti-aging effect of celecoxib might
be independent of its COX-2 inhibitory activity. In-
deed, celecoxib was shown to inhibit the activity of
3’-phosphoinositide-dependent kinase-1 (PDK-1), a
key component of the insulin/IGF-1 signaling cascade
that is involved in lifespan regulation in C. elegans.
Other studies have demonstrated that NSAIDs have
antioxidative effects through anti-radical activity and
membrane-stabilizing action [44, 45].
Thus, NSAIDs might be effective for slowing aging
and prevention of age-related diseases through not
only their anti-inflammatory effects via COX-2
inhibitory action but through potential secondary
targets including PDK-1 inhibition and the anti-
oxidative effect.
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Triglycerides and NSAIDs
The triglyceride values (TG, Neutral fat value) are one of
the three indices characterizing metabolic syndrome.
Metabolic syndrome is evoked by an accumulation of
abdominal fat, and, as previously mentioned, several
obesity-associated cancers [46] may occur.
The serum TG value is correlated with a high-fat diet
and is higher in patients in an obese state. When the
serum TG value increases, colorectal adenomas (often in
such as colon polyps) are more likely to occur. This oc-
currence has been noted in several epidemiological stud-
ies. For example, high TGs in hypertriglyceridemia were
associated with colorectal adenoma (OR = 1.5, 95 % CI,
1.1–2.0 for the highest versus the lowest quartile, P trend =
0.03). A stronger association was observed between three
or more adenoma cases and study controls (OR = 2.3,
95 % CI, 1.3–4.2, P trend < 0.001) [7]. In Japanese men, risk
of CRC is increased under high-TG levels [6]. Animal ex-
periments supported the relation between high-TG and
carcinogenesis by explaining the underlying mechanisms.
Thus, high TG might be understood as a risk factor for
CRC [47, 48].
On the other hand, there are a variety of discussions
about whether NSAIDs can adjust the TG value.
NSAIDs can inhibit the enzymatic activity of COX and
attenuate the expression level of PGE2. PGE2 is activated
through an EP3 receptor at the thermoregulatory center
in the hypothalamus and functions to raise the set point
of body temperature by increasing the cellular metabol-
ism. This linkage means NSAIDs decrease TG levels.
Furthermore, PGE2 induces the expression of TNFα, and
the TG value also increases because of the inhibition of
lipoprotein lipase (LPL) [49]. LPL catalyzes the hydroly-
sis of plasma TG.
The lowering of the TG value by NSAIDs is also found
in several studies in the literature. For example, when
NSAIDs were used in animal experimental models, they
significantly reduced the total cholesterol, TG and low-
density lipoprotein (LDL) concentrations in the plasma
of hyperlipidemic rats [49, 50].
Niho et al. investigated the influence of the general
COX inhibitor, indomethacin, in Min mice and found
that treatment with 10 ppm indomethacin in the diet for
14 weeks caused 90 % reduction in serum TG values,
along with a reduction in the number of intestinal
polyps to 25 % of the untreated control value [51]. In
this experiment, LPL mRNA levels in the liver were
slightly increased by indomethacin treatment. In
humans, indomethacin does not affect serum lipids.
In another model animal experiment, aspirin could
improve serum high-TG. Human apolipoprotein CI
(apoCI)-expressing mice (APOC1 mice), an animal
model with elevated plasma TG levels, as well as normo-
lipidemic wild-type mice, were fed a high-fat diet and
treated with aspirin. Aspirin treatment reduced hepatic
NF-κB activity in high-fat diet-fed APOC1 and wild-type
mice, and in addition, aspirin decreased plasma TG
levels (−32 %, P < 0.05) in hypertriglyceridemic APOC1
mice. This TG-lowering effect could not be explained by
enhanced VLDL-TG clearance, but aspirin selectively re-
duced hepatic production of VLDL-TG in both APOC1
(−28 %, P < 0.05) and wild-type mice (−33 %, P < 0.05)
without affecting VLDL-apoB production [52]. In
humans, higher proportions of patients in the salsalate
(one of the NSAIDS) treatment groups experienced de-
creasing circulating TG values and increasing adiponec-
tin concentrations [53]. For preventing colorectal
carcinogenesis, significant consideration should be given
to the use of NSAIDs to decrease plasma TG levels.
Smoking and NSAIDs
Smoking is a strong risk factor for the incidence of
colorectal adenomas [7] but a weak risk factor for the
colorectal adenocarcinomas [54]. Conversely, NSAIDs
including aspirin are known to reduce the adenoma
recurrence rate. Evidence has accumulated that shows
current smoking abrogates or inversely affects the use
of aspirin.
We recently performed two trials using enteric-coated
aspirin and found that aspirin similarly increased the
risk of colorectal adenomas in current smokers [55].
One of these trials is the J-CAPP Study [56]. It is a ran-
domized controlled trial involving 311 patients from
Asia with colorectal adenomas and/or early-stage adeno-
carcinomas (adenocarcinomas with invasions confined
to the mucosa) that evaluated the effects of 100 mg/day
enteric-coated aspirin for two years. In subgroup ana-
lyses, we found a reduced adenoma recurrence rate with
an OR of 0.37 (95 % CI, 0.21–0.68) in non-smokers
(never-smokers/ex-smokers) and 3.45 (95 % CI, 1.12–
10.64) in current smokers. The other trial is the J-FAPP
Study II [57]. It is also a randomized controlled trial. It
involved 34 subjects with Asian familial adenomatous
polyposis that evaluated the effects of 100 mg/day
enteric-coated aspirin for 6 to 10 months. In the trial,
the OR for a reduction in the diameter of polyps was
0.10 (95 % CI, 0.01–0.98) in non-smokers and 3.00 (95
% CI, 0.15–59.89) in current smokers.
After our findings, two papers confirmed the effects of
aspirin use on the status of smoking for colorectal aden-
oma recurrence. A randomized, double-blind, placebo-
controlled trial was performed at centers in Europe,
Russia, or the US using 75 mg aspirin for 3 years for pa-
tients with 1 or more sporadic adenomas removed from
the colon or rectum [58]. Its subgroup analyses revealed
OR values of 0.65 (95 % CI, 0.26 − 1.22) and 1.70 (95 %
CI, 0.70–4.09) in non-smokers and current smokers, re-
spectively. The other paper was a cross-sectional study
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including 2,918 consecutive colonoscopy patients over a
30-month period at a university hospital in the US [59].
The incidental rate ratio (IRR) of polyps was 1.72 (95 %
CI, 1.46–2.02) in active smokers and 0.73 (95 % CI,
0.61–0.86) in daily aspirin users compared to those with-
out aspirin. Current smoking interacts significantly with
aspirin, resulting in an IRR of 1.69 (95 % CI, 1.28–2.24)
that shows loss of aspirin protection.
The mechanism by which smoking influences the ef-
fect of aspirin is unknown. One clue is that smoking
may be associated with resistance to aspirin, possibly
through excessive thromboxane production [60, 61].
Further studies are warranted because this issue is very
important for the clinical use of aspirin in the future.
Conclusion with recent recommendation of low-
dose aspirin
On September 15, 2015, the U.S. Preventive Services
Task Force (USPSTF) posted a draft recommendation
statement with several limitations about taking low-dose
aspirin every day to help prevent cardiovascular disease
(CVD), such as heart attack and stroke, and CRC [62].
They stated that patients aged 50–59 who have a 10 %
or greater 10-year CVD risk [63] but who are not at in-
creased risk for bleeding and have at least a 10-year life
expectancy fall within the USPSTF B recommendation
to take low-dose aspirin daily for at least 10 years. The
definition of the B recommendation is that there is high
certainty that the net benefit of low-dose aspirin is mod-
erate, or there is moderate certainty that the net benefit
is moderate to substantial [62].
The USPSTF also posted that it is insufficient to assess
the benefit and harm of aspirin use for those older than
80, and it recommended the use of aspirin for prevention
of stroke in women < 55 and for prevention of myocardial
infarction in men < 45. For several NSAIDs, such as diclo-
fenac, the NSAIDs will increase the risk of death and re-
current myocardial infraction in patients with prior
myocardial infraction [64]. From our data, smoking status
should be included in the USPSTF recommendation state-
ment. Use of NSAIDs for pain relief may increase physical
activation in a convincing way to reduce the risk of CRC
[4]. It will be worthwhile to know the effects of NSAIDs
on the risk factors of CRC and utilize them for a person’s
physical health as well as to prevent CRC.
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